Estudios originales
Published on 24 de septiembre de 2024 | http://doi.org/10.5867/medwave.2024.08.2923
Fulvestrant in clinical practice: Effectiveness analysis in Uruguayan patients with HR+/HER2- breast cancer
Back to article
Multivariate analysis of factors associated with OS.
| < 65 | a | a | ||
| ≥ 65 | 1.10 | 0.151 | 1.15 | 0.063 |
| Male | a | a | ||
| Female | 1.05 | 0.873 | 1.04 | 0.905 |
| Montevideo | a | |||
| Rest of the country | 0.98 | 0.726 | ||
| Private | a | a | ||
| Public | 0.79 | 0.0185 | 0.82 | 0.063 |
| Functional statusa | ||||
| 0 | a | |||
| a | 1.51 | <0.001 | ||
| 2 | 2.02 | 0.007 | ||
| No | a | a | ||
| Yes | 1.26 | 0.006 | 1.21 | 0.035 |
| No | a | |||
| Yes | 1.08 | 0.322 | ||
| No | a | |||
| Yes | 1.60 | <0.001 | ||
| No | a | |||
| Yes | 0.84 | 0.080 | ||
| No | a | |||
| Yes | 1.21 | 0.446 |
OS, overall survival.
aPerformance status and presence of liver metastases variables were used to stratify the model because they showed non-proportionality in the risks.
Source: Prepared by the authors of this study.